ReviewFrontiers in cardiovascular medicine2026
The pathophysiological role of MiRNAs in heart failure.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) is a growing global health issue, chiefly marked by inexorable myocyte loss, maladaptive remodeling, and energetic failure. MicroRNAs (miRNAs) function as the principal post-transcriptional regulators of gene networks capable of facilitating the pathophysiology of illnesses. However, there is limited systemic-level understanding of their participation in human HF. Therefore, the miRNA mechanisms that modulate apoptosis, autophagy, myocardial fibrosis, inflammatory response, and energy metabolism of cardiomyocytes to inhibit and treat HF are elucidated in this work. Method: A analysis of the mechanisms utilized by miRNAs in the modulation of HF was performed following the retrieval of literature on the mechanism of action of miRNAs in HF. The literature was obtained from PubMed and Web of Science databases between 2021 and 2025. Result: The multi-dimensional regulatory function of miRNAs in HF was uncovered. At the cellular fate level, they mediate the survival and death of the myocardium and inhibit excessive apoptosis and oxidative damage. At the organizational structure level, they inhibit the advancement of pathological ventricular remodeling and fibrosis. At the energy homeostasis level, they control autophagy and energy metabolism of cells. Finally, at the inflammatory and signaling levels, they suppress the inflammatory storm and maintain calcium signaling homeostasis. A sophisticated and dynamic regulatory system consisting of various miRNAs was observed, which offers a theoretical basis and potential targets for HF mechanism research and targeted intervention. Conclusion: MicroRNAs (miRNAs) jointly affect the survival, remodeling and energy balance of cardiac muscle cells. However, the clinical application of miRNAs in HF is still in the early exploration stage, and their true diagnostic value and therapeutic potential need to be further confirmed by rigorous and large-scale clinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.